Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

Polynovo stock

PNV.AX
AU000000PNV0
A12F4T

Price

2.07
Today +/-
-0.01
Today %
-0.66 %

Polynovo stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Polynovo stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Polynovo stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Polynovo stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Polynovo's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Polynovo Stock Price History

DatePolynovo Price
12/18/20242.07 undefined
12/17/20242.08 undefined
12/16/20242.07 undefined
12/13/20242.06 undefined
12/12/20242.10 undefined
12/11/20242.11 undefined
12/10/20242.16 undefined
12/9/20242.23 undefined
12/6/20242.21 undefined
12/5/20242.27 undefined
12/4/20242.23 undefined
12/3/20242.25 undefined
12/2/20242.19 undefined
11/29/20242.21 undefined
11/28/20242.16 undefined
11/27/20242.15 undefined
11/26/20242.08 undefined
11/25/20242.03 undefined
11/22/20241.98 undefined
11/21/20241.98 undefined
11/20/20242.03 undefined
11/19/20242.05 undefined

Polynovo Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Polynovo, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Polynovo from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Polynovo’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Polynovo. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Polynovo’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Polynovo’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Polynovo’s growth potential.

Polynovo Revenue, EBIT and net profit per share

DatePolynovo RevenuePolynovo EBITPolynovo Net Income
2030e267.28 M undefined0 undefined51.63 M undefined
2029e242.93 M undefined60.57 M undefined44.31 M undefined
2028e220.92 M undefined47 M undefined36.91 M undefined
2027e211.52 M undefined45.56 M undefined35.65 M undefined
2026e170.07 M undefined27.07 M undefined22.17 M undefined
2025e135.86 M undefined10.28 M undefined9.54 M undefined
2024104.73 M undefined2.7 M undefined5.26 M undefined
202366.11 M undefined-5.32 M undefined-4.92 M undefined
202241.44 M undefined-255,990 undefined-1.19 M undefined
202129.16 M undefined-3.15 M undefined-4.61 M undefined
202022.19 M undefined-4.07 M undefined-4.19 M undefined
201913.68 M undefined-3.54 M undefined-3.19 M undefined
20185.99 M undefined-6.21 M undefined-5.97 M undefined
20173.76 M undefined-5.01 M undefined-5.01 M undefined
20163.47 M undefined-3.33 M undefined-3.06 M undefined
2015140,720 undefined-2.93 M undefined-1.3 M undefined
2014270,000 undefined-2.94 M undefined-2.94 M undefined
2013280,000 undefined-1.57 M undefined-1.49 M undefined
2012810,000 undefined-2.83 M undefined-2.7 M undefined
2011910,000 undefined-3.35 M undefined-2.92 M undefined
2010630,000 undefined-2.72 M undefined-1.86 M undefined
2009980,000 undefined-2 M undefined-1.83 M undefined
20081.32 M undefined-3.79 M undefined-4.44 M undefined
20071.43 M undefined-12.59 M undefined-13.41 M undefined
20061.29 M undefined-10.52 M undefined-11.29 M undefined
2005790,000 undefined-10.77 M undefined-10.77 M undefined

Polynovo Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025e2026e2027e2028e2029e2030e
000002011100000003351322294166104135170211220242267
-------------------66.67160.0069.2331.8241.3860.9857.5829.8125.9324.124.2710.0010.33
-----4,950.00-9,900.009,900.009,900.00-------3,300.00133.33100.0092.3190.9193.1095.1292.4295.1973.3358.2446.9245.0040.9137.08
00000000000000000045122027396199000000
-1-3-5-5-8-9-10-11-13-4-1-1-2-2-1-2-1-3-5-5-3-4-4-1-4592235364451
-200.0066.67-60.0012.5011.1110.0018.18-69.23-75.00-100.00--50.00100.00-50.00200.0066.67--40.0033.33--75.00300.00-225.0080.00144.4459.092.8622.2215.91
110.43130.31140.37148160.29216.05230.11261.3293.14300.95301.45320.64346.63346.63347.48410.94418.51493.26561.76627.89659.66661.09661.19660.87684.45700.38000000
--------------------------------
Details

Keystats

ⓘ

Revenue and Growth

The Polynovo Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Polynovo is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (k)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (k)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (k)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (k)OTHER LIAB. (k)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
19992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024
                                                   
5.4310.365.6212.086.8517.3517.0823.320.5816.4712.246.047.224.873.944.733.5210.85.5522.213.9711.77.746.1546.945.96
000000000000000000.70.491.472.482.95.375.9213.3619.93
000000000000000000.860.881.211.921.020.440.320.670.8
0000000000000000000.981.081.221.221.962.544.538.97
0.130.040.020.090.230.080.130.10.160.090.210.210.2000.010.010.040.060.160.312.440.731.261.93.64
5.5610.45.6412.177.0817.4317.2123.420.7416.5612.456.257.424.873.944.743.5312.397.9626.1319.919.2816.2416.1967.3579.3
0.010.020.040.30.290.970.830.710.550.291.841.681.471.291.090.951.010.991.451.146.0116.5419.8216.7523.3724.17
0000000.50.490.490.140.234.490.130.160.240.210.220.120.120.160.170.140.140.30.560
0000000000000000000000475.52329.21182.890
1.51.51.500000002.522.522.522.522.522.522.522.522.522.42.151.91.651.41.160.91
00000000000000000000000000
00000000000000000000000.140.30.564.35
1.511.521.540.30.290.971.331.21.040.434.598.694.123.973.853.683.743.634.13.78.3318.5822.2419.0825.8329.42
7.0711.927.1812.477.3718.418.5424.621.7816.9917.0414.9411.548.847.798.427.2716.0212.0629.8228.2337.8638.4835.2793.18108.72
                                                   
8.0116.3816.427.8730.5550.4261.7878.2489.0889.0889.0890.3690.3690.3691.5894.8794.87114.1114.48138.12139.07139.07139.25139.43191.59191.6
00000000000000000000000000
-1.35-4.92-9.99-15.72-24.29-33.73-44.5-55.47-68.28-72.62-74.51-76.95-79.7-82.36-83.81-86.26-87.42-98.99-103.66-109.5-112.6-114.73-116.71-121.38-125.19-118.57
0000000-0.01-0.010000000000-0.16-0.38-0.53-0.19-0.33-1.02-0.91
000000000020340203090100103.75000000000
6.6611.466.4112.156.2616.6917.2822.7620.7916.4614.5913.7510.688.037.868.717.5615.1110.8128.4626.123.8122.3517.7265.3872.12
0.410.490.790.431.161.871.211.950.950.090.410.410.430.420.260.210.130.410.420.220.581.611.811.872.746.39
0.010.010.030.040.040.070.160.20.220.590.070.050.050.060.070.120.070.120.180.280.310.610.7411.642.24
00000000000.20.450.420.10.180.170.280.180.470.721.171.633.223.16.412.08
000000000000000000000000383.99815
0000000000000000000005.632.881.791.511.72
0.420.50.820.471.21.941.372.151.170.680.680.910.90.580.510.50.490.711.071.222.069.478.657.7612.6723.25
0000000000000000000004.47.129.2114.1512.85
000000000076034020070000000000000
0000203040406020303040270290250243.41207.31173.39144.5465.04166.83215.96293.49416.61504
00000.020.030.040.040.060.020.790.370.240.340.290.250.240.210.170.140.074.577.349.514.5713.35
0.420.50.820.471.221.971.412.191.230.71.471.281.140.920.80.750.730.911.241.362.1314.0415.9917.2627.2436.6
7.0811.967.2312.627.4818.6618.6924.9522.0217.1616.0615.0311.828.958.669.468.2916.0212.0629.8228.2337.8638.3434.9792.62108.72
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Polynovo provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Polynovo's financial health and stability.

Assets

Polynovo's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Polynovo must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Polynovo after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Polynovo's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (k)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
1999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
00000000000000000000000-1-4
0000000000000000000000012
0000000000000000000000000
0000031111000100100100000
00000000000000000000000-2,0001,000
0000000000000000000000000
0000000000000000000000000
-1-3-4-4-7-8-10-10-13-4-3-2-2-2-2-2-2-3-5-6-300-2-6
00000000000000000000-6-8-30-1
00000000000-30201100-1913-8-350
00000000000-30201100-18190060
0000000000000000000000000
00000000000000000000070-5-3
680122191116100000013013023000052
680112191116100000013010023070-548
------------------2.00-------
0000000000000000000000000
31-101-14-1-12-5-17-9-7-9-6-4-3-1-42-11-106-3-3-334
-1.36-3.43-4.76-5.02-7.91-9.37-11.13-10.28-13.57-4.13-4.01-2.91-2.97-2.73-2.34-2.69-2.88-3.76-5.74-7.1-9.89-9.3-3.82-2.55-8.14
0000000000000000000000000

Polynovo stock margins

The Polynovo margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Polynovo. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Polynovo.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Polynovo's sales revenue. A higher gross margin percentage indicates that the Polynovo retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Polynovo's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Polynovo's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Polynovo's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Polynovo. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Polynovo's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Polynovo Margin History

Polynovo Gross marginPolynovo Profit marginPolynovo EBIT marginPolynovo Profit margin
2030e94.77 %0 %19.32 %
2029e94.77 %24.93 %18.24 %
2028e94.77 %21.28 %16.71 %
2027e94.77 %21.54 %16.86 %
2026e94.77 %15.92 %13.04 %
2025e94.77 %7.57 %7.02 %
202494.77 %2.58 %5.02 %
202393.29 %-8.04 %-7.45 %
202294.68 %-0.62 %-2.88 %
202194.67 %-10.79 %-15.79 %
202092.32 %-18.33 %-18.9 %
201990.54 %-25.84 %-23.31 %
201889.43 %-103.64 %-99.74 %
2017122.51 %-133.17 %-133.17 %
201694.77 %-95.97 %-88.22 %
201594.77 %-2,079.83 %-925.56 %
201494.77 %-1,088.89 %-1,088.89 %
201394.77 %-560.71 %-532.14 %
201294.77 %-349.38 %-333.33 %
201194.77 %-368.13 %-320.88 %
201094.77 %-431.75 %-295.24 %
200994.77 %-204.08 %-186.73 %
200894.77 %-287.12 %-336.36 %
200794.77 %-880.42 %-937.76 %
200694.77 %-815.5 %-875.19 %
200594.77 %-1,363.29 %-1,363.29 %

Polynovo Stock Sales Revenue, EBIT, Earnings per Share

The Polynovo earnings per share therefore indicates how much revenue Polynovo has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Polynovo earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Polynovo's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Polynovo’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Polynovo's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Polynovo Revenue, EBIT and net profit per share

DatePolynovo Sales per SharePolynovo EBIT per sharePolynovo Earnings per Share
2030e0.39 undefined0 undefined0.07 undefined
2029e0.35 undefined0 undefined0.06 undefined
2028e0.32 undefined0 undefined0.05 undefined
2027e0.31 undefined0 undefined0.05 undefined
2026e0.25 undefined0 undefined0.03 undefined
2025e0.2 undefined0 undefined0.01 undefined
20240.15 undefined0 undefined0.01 undefined
20230.1 undefined-0.01 undefined-0.01 undefined
20220.06 undefined-0 undefined-0 undefined
20210.04 undefined-0 undefined-0.01 undefined
20200.03 undefined-0.01 undefined-0.01 undefined
20190.02 undefined-0.01 undefined-0 undefined
20180.01 undefined-0.01 undefined-0.01 undefined
20170.01 undefined-0.01 undefined-0.01 undefined
20160.01 undefined-0.01 undefined-0.01 undefined
20150 undefined-0.01 undefined-0 undefined
20140 undefined-0.01 undefined-0.01 undefined
20130 undefined-0 undefined-0 undefined
20120 undefined-0.01 undefined-0.01 undefined
20110 undefined-0.01 undefined-0.01 undefined
20100 undefined-0.01 undefined-0.01 undefined
20090 undefined-0.01 undefined-0.01 undefined
20080 undefined-0.01 undefined-0.01 undefined
20070 undefined-0.04 undefined-0.05 undefined
20060 undefined-0.04 undefined-0.04 undefined
20050 undefined-0.05 undefined-0.05 undefined

Polynovo business model

Polynovo Ltd is an Australian BioTech company that specializes in the development and manufacturing of medical implants. The company was founded in 1986 under the name Regeneus Ltd and is headquartered in Melbourne. Polynovo's history began with the development of products for the veterinary field. In 2000, the company received approval for the sale of its first human products, which were used for wound treatment. In 2014, the company was renamed Polynovo to emphasize its focus on biological implants for human tissue. Polynovo utilizes a revolutionary technology called NovoSorb, which allows for the production of biodegradable polymer films in various shapes and sizes. These are then used as implants in the human body and naturally degrade within a predetermined timeframe. Polynovo is divided into various divisions, including wound care, plastic surgery, and orthopedics. In wound care, the company offers products that aim to prevent infections and promote natural healing processes. The plastic surgery division provides implants for breast reconstruction and fat transplantation. In orthopedics, Polynovo manufactures implants for joints, bones, and tendons. An example of a Polynovo product is NovoSorb BTM (Biodegradable Temporary Matrix), which is used in burns and other skin defects. The matrix stimulates healing and the formation of new tissue, restoring a normal appearance to the patient. Polynovo's business model is based on long-term relationships with hospitals, medical professionals, and government agencies. The company heavily invests in research and development to continuously improve and expand its technology and product range. Through partnerships with other companies and academic institutions, Polynovo is working towards global distribution of its products. Overall, Polynovo has received various awards over the years, including an innovation award from the Australian Trade Commission, and has been recognized multiple times as one of Australia's fastest-growing companies. In conclusion, Polynovo is an innovative and successful company specializing in the development and manufacturing of biological implants. Thanks to its NovoSorb technology, the company can offer products that help accelerate the healing process and facilitate faster patient recovery. Polynovo is one of the most popular companies on Eulerpool.com.

Polynovo SWOT Analysis

Strengths

  • Polynovo Ltd has a strong research and development team, enabling them to continuously innovate and develop new products.
  • The company's patented NovoSorb biodegradable polymer technology provides a distinct competitive advantage in the market.
  • Strong financial performance and steady revenue growth have allowed the company to invest in expansion and infrastructure.
  • Polynovo has a diverse and global customer base, reducing dependence on any single market or customer.

Weaknesses

  • Limited market presence and brand recognition compared to more established competitors.
  • Reliance on a few key suppliers for raw materials, which may expose the company to supply chain risks.
  • High production costs due to the complexity of the manufacturing process and the use of advanced technology.
  • Limited product portfolio, with a focus primarily on medical devices for burn treatment.

Opportunities

  • Growing demand for biodegradable polymers in various industries presents an opportunity for Polynovo to expand its product portfolio.
  • Increasing global healthcare expenditure and the need for advanced wound care products creates a favorable market environment for the company.
  • The potential to enter new geographic markets and form strategic partnerships to accelerate growth.
  • Expansion into other medical device verticals beyond burn treatment, such as wound healing or surgical applications.

Threats

  • Intense competition from larger and more established medical device companies with greater resources and market presence.
  • Regulatory challenges and compliance requirements in different markets may pose obstacles to market entry and product approvals.
  • Economic downturns and fluctuations in healthcare spending could negatively impact Polynovo's sales and growth.
  • Technological advancements or breakthroughs by competitors could render Polynovo's existing products less competitive or obsolete.
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Polynovo Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Polynovo historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Polynovo shares outstanding

The number of shares was Polynovo in 2023 — This indicates how many shares 684.454 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Polynovo earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Polynovo's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Polynovo’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Polynovo's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Polynovo.

Polynovo latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/20240 0  (60 %)2024 Q4
12/31/20230 0  (0 %)2024 Q2
6/30/2023-0.01 -0.01  (-14.75 %)2023 Q4
12/31/20220 -0.01  (-400 %)2023 Q2
6/30/2021-0 -0  (-100 %)2021 Q4
1

Eulerpool ESG Scorecard© for the Polynovo stock

Eulerpool World ESG Rating (EESG©)

34/ 100

🌱 Environment

1

👫 Social

63

🏛️ Governance

36

Environment

Scope 1 - Direct Emissions
Scope 2 - Indirect emissions from purchased energy
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees36
Percentage of women in management
Percentage of Asian employees26
Share of Asian management36
Percentage of Hispanic/Latino employees4
Hispano/Latino Management share3
Percentage of Black employees9
Black Management Share8
Percentage of white employees60
White Management Share53
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Polynovo shareholders

%
Name
Stocks
Change
Date
4.99597 % The Vanguard Group, Inc.34,514,14217,163,5546/18/2024
3.10077 % Williams (David John)21,421,38506/30/2024
3.08616 % State Street Global Advisors Australia Ltd.21,320,44519,641,4399/24/2024
1.80557 % Vanguard Investments Australia Ltd.12,473,581-23,6869/30/2024
1.58128 % Lateral Innovations Pty. Ltd.10,924,10308/7/2024
1.31043 % Allianz Global Investors Asia Pacific Limited9,053,000-800,0007/31/2024
1.25034 % BlackRock Institutional Trust Company, N.A.8,637,84726,1879/30/2024
1.16525 % Kittel (Anthony Shane)8,050,000-5,7898/7/2024
0.99804 % Kenley (David)6,894,8553,755,0008/7/2024
0.92955 % State Street Global Advisors (US)6,421,7304,580,9729/24/2024
1
2
3
4
5
...
8

Polynovo Executives and Management Board

Mr. Swami Raote

Polynovo Chief Executive Officer
Compensation 1.69 M

Dr. David McQuillan

Polynovo Chief Technical and Scientific Officer (since 2012)
Compensation 565,110

Mr. Jan Gielen

Polynovo Chief Financial Officer, Company Secretary
Compensation 291,634

Mr. David Williams

Polynovo Non-Executive Independent Chairman of the Board
Compensation 140,000

Dr. Robyn Elliott

Polynovo Non-Executive Director
Compensation 95,432
1
2

Polynovo Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Establishment Labs Holdings Stock
Establishment Labs Holdings
SupplierCustomer0,49-0,62-0,26-0,230,66-0,27
Premier A Stock
Premier A
SupplierCustomer0,240,370,240,80-0,13-0,45
1

Most common questions regarding Polynovo

What values and corporate philosophy does Polynovo represent?

Polynovo Ltd represents a strong set of values and an innovative corporate philosophy. The company is committed to delivering advanced medical solutions using their unique NovoSorb® technology platform. Polynovo focuses on improving patient outcomes by providing safe and effective products for the healthcare industry. Their dedication to research and development allows them to create cutting-edge solutions that address critical needs in wound healing and soft tissue repair. With a customer-centric approach, Polynovo strives to make a positive impact on healthcare by offering innovative products and maintaining high standards of quality, safety, and ethics.

In which countries and regions is Polynovo primarily present?

Polynovo Ltd is primarily present in Australia and the United States.

What significant milestones has the company Polynovo achieved?

Polynovo Ltd has achieved several significant milestones in recent years. First and foremost, the company successfully developed and commercialized its innovative NovoSorb BTM technology. This breakthrough technology has revolutionized the treatment of complex wounds, allowing for faster and more effective healing. Another notable milestone for Polynovo Ltd was its expansion into international markets, securing regulatory approvals in Europe, the United States, and other key regions. Additionally, the company has formed strategic partnerships with global healthcare companies, further strengthening its position in the market. These achievements demonstrate Polynovo Ltd's commitment to providing cutting-edge solutions for wound care management and its continuous growth in the industry.

What is the history and background of the company Polynovo?

Polynovo Ltd is an Australian medical device company specializing in the design, development, and manufacturing of dermal regeneration solutions. Established in 1998, Polynovo has become a global leader in its field, with its flagship product NovoSorb® BTM gaining significant recognition. This innovative biodegradable scaffold facilitates the regeneration of full-thickness skin and helps treat various wounds, burns, and surgical incisions. Polynovo's commitment to advanced technology, research, and development has enabled them to establish a strong presence in international markets, providing medical professionals and patients with effective and lasting solutions for improved healing outcomes.

Who are the main competitors of Polynovo in the market?

The main competitors of Polynovo Ltd in the market include larger medical device companies such as Johnson & Johnson, Medtronic, and Zimmer Biomet. These companies also offer innovative and competitive products in the field of medical device manufacturing. However, Polynovo Ltd distinguishes itself with its unique patented NovoSorb platform, which is highly regarded for its biocompatible and bioresorbable capabilities. Polynovo Ltd aims to revolutionize the market with its innovative medical solutions, providing patients with advanced options for wound care and tissue repair.

In which industries is Polynovo primarily active?

Polynovo Ltd is primarily active in the medical industry, specifically specializing in the development, manufacturing, and commercialization of medical devices. The company's innovative technologies focus on the treatment of acute and chronic wounds, including burns, surgical wounds, and skin defects. Polynovo's products, such as its leading NovoSorb BTM technology, offer surgeons and patients advanced wound healing solutions. With a strong commitment to research and development, Polynovo aims to cater to the growing global demand for effective wound care and tissue regeneration products.

What is the business model of Polynovo?

The business model of Polynovo Ltd, an Australian medical device company, is centered around the development, manufacturing, and commercialization of its innovative biodegradable polymer technologies for the medical industry. Polynovo's core product is NovoSorb, a revolutionary biomaterial that can be used in various medical applications, such as wound management, surgical procedures, and tissue regeneration. By harnessing the benefits of NovoSorb, Polynovo aims to provide healthcare professionals with advanced solutions that improve patient outcomes and reduce healthcare costs. With its focus on research, technology, and collaboration, Polynovo Ltd strives to establish itself as a leading player in the global medical device market.

What is the P/E ratio of Polynovo 2024?

The Polynovo P/E ratio is 275.09.

What is the P/S ratio of Polynovo 2024?

The Polynovo P/S ratio is 13.82.

What is the Quality Investing of Polynovo?

The Quality Investing for Polynovo is 4/10.

What is the revenue of Polynovo 2024?

The Polynovo revenue is 104.73 M AUD.

How high is the profit of Polynovo 2024?

The Polynovo profit is 5.26 M AUD.

What is the business model of Polynovo

Polynovo Ltd is an Australian company specializing in the manufacture of medical products. The company's business model is based on offering various products divided into three main areas: wound care, surgery, and traumatology. Polynovo develops innovative and advanced medical products for wound healing, surgery, and traumatology. The company uses bioresorbable materials to accelerate the healing process and reduce the risk of infections. Polynovo invests significant resources in research and development to maintain technological leadership in this field. The company sells its products directly to hospitals, healthcare providers, wound healing and surgery professionals. Polynovo aims to expand its reach and enter new markets to promote business growth. The company's business model is focused on solving people's health issues and enabling a better life.

What is the Polynovo dividend?

Polynovo pays a dividend of 0 AUD distributed over payouts per year.

How often does Polynovo pay dividends?

The dividend cannot currently be calculated for Polynovo or the company does not pay out a dividend.

What is the Polynovo ISIN?

The ISIN of Polynovo is AU000000PNV0.

What is the Polynovo WKN?

The WKN of Polynovo is A12F4T.

What is the Polynovo ticker?

The ticker of Polynovo is PNV.AX.

How much dividend does Polynovo pay?

Over the past 12 months, Polynovo paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Polynovo is expected to pay a dividend of 0 AUD.

What is the dividend yield of Polynovo?

The current dividend yield of Polynovo is .

When does Polynovo pay dividends?

Polynovo pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Polynovo?

Polynovo paid dividends every year for the past 0 years.

What is the dividend of Polynovo?

For the upcoming 12 months, dividends amounting to 0 AUD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Polynovo located?

Polynovo is assigned to the 'Health' sector.

Wann musste ich die Aktien von Polynovo kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Polynovo from 12/18/2024 amounting to 0 AUD, you needed to have the stock in your portfolio before the ex-date on 12/18/2024.

When did Polynovo pay the last dividend?

The last dividend was paid out on 12/18/2024.

What was the dividend of Polynovo in the year 2023?

In the year 2023, Polynovo distributed 0 AUD as dividends.

In which currency does Polynovo pay out the dividend?

The dividends of Polynovo are distributed in AUD.

All fundamentals about Polynovo

Our stock analysis for Polynovo Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Polynovo Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.